Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Serina Therapeutics ( (SER) ) just unveiled an update.
Serina Therapeutics, Inc. has solidified its leadership by appointing Steven Ledger as the permanent CEO after his interim tenure. With over 35 years of industry experience, Ledger brings a wealth of knowledge from various advisory and operational roles in early-stage companies and venture capital. His compensation package includes a $450,000 base salary, potential for 50% incentive, and stock options, aligning his interests with the company’s strategic goals. The agreement also contains non-compete and non-solicitation clauses, ensuring Ledger’s commitment to Serina Therapeutics’ success.
See more insights into SER stock on TipRanks’ Stock Analysis page.
